Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin.

Int J Mol Sci · 2019 · PMC6470641 · PMID 30917505

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

In advanced-stage HCC patients, a favorable trend of PFS and OS for patients with low expression of p-mTOR suggested this marker as a promising therapeutic target for HCC treatment, in line with other studies [ 15 , 32 , 33 ].

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.